Drug intelligence / Profile preview

gemcitabine + fluorouracil + aldesleukin + interferon alfa

Development stage: Unknown
Lead developer: Cancer Biotherapy Research Group
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

gemcitabine + fluorouracil + aldesleukin + interferon alfa is a combination chemobiotherapy regimen investigated by the Cancer Biotherapy Research Group for the treatment of metastatic or unresectable renal cell carcinoma. This regimen integrates cytotoxic chemotherapy with biological response modifiers to achieve a synergistic antitumor effect. Gemcitabine and fluorouracil are antimetabolites that interfere with DNA synthesis and repair, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Aldesleukin (recombinant interleukin-2) and interferon alfa are cytokines that modulate the host immune system, enhancing the proliferation and activity of cytotoxic T-cells and natural killer (NK) cells against tumor targets. By combining direct cytotoxicity with immune stimulation, the regimen aims to overcome the resistance often observed in advanced renal cell carcinoma.

Other names: Gemcitabine/5-FU/IL-2/IFN-alpha combinationChemobiotherapy (Gem/5-FU/IL-2/IFN-alpha)

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)TS (Thymidylate synthase)IFNAR (Immune system modulation via type I interferon receptor)DNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on gemcitabine + fluorouracil + aldesleukin + interferon alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + fluorouracil + aldesleukin + interferon alfa.

Explore the full profile